MarketBeat
25 Oct 2026, 06:07 UTC · 2h ago
Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands
Impact · against what's priced in
PVLA is emerging as a potential commercial-stage biotech with a clear PDUFA timeline for April 2027 and significant peak sales potential ($1B-$3B). The transition from a single-indication company to a multi-indication platform with a second active ingredient (pitavastatin) provides a catalyst for growth beyond the initial MLM launch.
- PVLA+0.70
No priced-in read yet
- In context
The company provided a specific PDUFA target of April 2027 for QTORIN rapamycin in MLM and quantified peak sales potential at $1B to $3B across MLM and CVM, while expanding the platform to include pitavastatin.
Read from the article alone
